PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib vs gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement

被引：0

作者：

Abou-Alfa, G. ^{[1
]}

Borbath, I. ^{[2
]}

Goyal, L. ^{[3
]}

Lamarca, A. ^{[4
]}

Macarulla, T. ^{[5
]}

Oh, D. ^{[6
]}

Roychowdhury, S. ^{[7
]}

Sadeghi, S. ^{[8
]}

Shroff, R. ^{[9
]}

Soto, J. ^{[10
]}

Pedrioli, G. ^{[11
]}

Fumagalli, L. ^{[11
]}

Dambkowski, C. ^{[10
]}

Javle, M. ^{[12
]}

机构：

[1] Cornell Univ, Mem Sloan Kettering Canc Ctr, Weill Med Coll, New York, NY 10021 USA

[2] Clin Univ St Luc, Brussels, Belgium

[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[4] Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England

[5] Hosp Valle De Hebron, Barcelona, Spain

[6] Seoul Natl Univ, Coll Med, Seoul, South Korea

[7] Ohio State Comprehens Canc Ctr, Columbus, OH USA

[8] Univ Calif Los Angeles, David Geffen Sch Med, Santa Monica, CA USA

[9] Univ Arizona, Ctr Canc, Tucson, AZ USA

[10] QED Therapeut Inc, San Francisco, CA USA

[11] Helsinn Healthcare SA, Lugano, Switzerland

[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.04.107

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-16

引用

页码：S251 / S252

页数：2

共 50 条

[21] Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma including FGFR2 fusion or rearrangement: Updated data from an open-label, single-arm, multicenter phase II study (CIBI375A201 study).
Shi, Guoming
Huang, Xiaoyong
Wen, Tianfu
Song, Tianqiang
Kuang, Ming
Mou, Haibo
Bao, Lequn
Zhao, Hai-Tao
Zhao, Hong
Feng, Xielin
Zhang, Bixiang
Peng, Tao
Zhang, Yubao
Li, Xiangcheng
Yu, Hongsheng
Cao, Yu
Luo, Yang
Chen, Mingxia
Fan, Jia
Zhou, Jian
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16183 - E16183
[22] Abraxane plus cisplatin compared with gemcitabine plus cisplatin as first- line treatment in patients with metastatic triple-negative breast cancer (GAP): A multicenter, randomized, open-label, phase III trial
Hu, X.
Wang, B.
Zhang, J.
Wang, Z.
Sun, T.
Wang, S.
Teng, Y.
Yan, M.
Wang, X.
Jiang, Z.
Cai, L.
Pan, Y.
ANNALS OF ONCOLOGY, 2020, 31 : S354 - S354
[23] FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
Goyal, Lipika
Meric-Bernstam, Funda
Hollebecque, Antoine
Valle, Juan W.
Morizane, Chigusa
Karasic, Thomas Benjamin
Furuse, Junji
He, Yaohua
Soni, Nital
Benhadji, Karim A.
Bridgewater, John A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[24] Adjuvant gemcitabine plus cisplatin (GemCis) versus capecitabine (CAP) in patients (pts) with resected lymph node (LN)-positive extrahepatic cholangiocarcinoma (CCA): A multicenter, open-label, randomized, phase 2 study (STAMP).
Yoo, Changhoon
Jeong, Hyehyun
Kim, Kyu-Pyo
Hwang, Dae Wook
Lee, Jae-Hoon
Kim, Ki-Hun
Moon, Deok Bok
Lee, Myung Ah
Park, Se Jun
Park, Jin-Hong
Lee, Ji Sung
Ryoo, Baek-Yeol
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[25] A multicenter randomized, open-label, proof-of-concept, phase II trial comparing gemcitabine with and without IMM-101 in advanced pancreatic cancer.
Dalgleish, Angus George
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
[26] A multicenter, open-label phase II trial of secondline apatinib plus irinotecan in patients with advanced gastric cancer
Peng, Jianjun
Li, Yong
Xiao, Jianjun
Liu, Huaqiang
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[27] Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve
Gross-Goupil, Marine
Domblides, Charlotte
Lefort, Felix
Ravaud, Alain
BULLETIN DU CANCER, 2020, 107 (05) : ES1 - ES7
[28] Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Grivas, Petros
Garralda, Elena
Meric-Bernstam, Funda
Mellinghoff, Ingo K.
Goyal, Lipika
Harding, James J.
Dees, E. Claire
Bahleda, Rastislav
Azad, Nilofer S.
Karippot, Asha
Kurzrock, Razelle
Tabernero, Josep
Kononen, Juha
Ng, Matthew C. H.
Mehta, Rutika
Uboha, Nataliya V.
Bigot, Frederic
Boni, Valentina
Bowyer, Samantha E.
Breder, Valeriy
Cervantes, Andres
Chan, Nancy
Cleary, James M.
Dhawan, Mallika
Eefsen, Rikke L.
Ewing, James
Graham, Donna M.
Guren, Tormod K.
Won Kim, Jin
Koynov, Krassimir
Oh, Do-Youn
Redman, Rebecca
Yen, Chia-Jui
Spetzler, David
Roubaudi-Fraschini, Marie-Claude
Nicolas-Metral, Valerie
Ait-Sarkouh, Rafik
Zanna, Claudio
Ennaji, Abdallah
Pokorska-Bocci, Anna
Flaherty, Keith T.
CLINICAL CANCER RESEARCH, 2024, 30 (20) : 4572 - 4583
[29] Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase lb and randomized, open-label, multicenter, phase 2 trial in Japan
Watanabe, Satoshi
Yoshioka, Hiroshige
Sakai, Hiroshi
Hotta, Katsuyuki
Takenoyama, Mitsuhiro
Yamada, Kazuhiko
Sugawara, Shunichi
Takiguchi, Yuichi
Hosomi, Yukio
Tomii, Keisuke
Niho, Seiji
Yamamoto, Nobuyuki
Nishio, Makoto
Ohe, Yuichiro
Kato, Terufumi
Takahashi, Toshiaki
Kamada, Ami
Suzukawa, Kazumi
Omori, Yukie
Enatsu, Sotaro
Nakagawa, Kazuhiko
Tamura, Tomohide
LUNG CANCER, 2019, 129 : 55 - 62
[30] Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial
Kim, S. T.
Kang, J. H.
Lee, J.
Lee, H. W.
Oh, S. Y.
Jang, J. S.
Lee, M. A.
Sohn, B. S.
Yoon, S. Y.
Choi, H. J.
Hong, J. H.
Kim, M. -J.
Kim, S.
Park, Y. S.
Park, J. O.
Lim, H. Y.
ANNALS OF ONCOLOGY, 2019, 30 (05) : 788 - 795

← 1 2 3 4 5 →